Qrons Inc.

Equities

QRON

US74737F1012

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:55:39 2024-03-08 EST			5-day change	1st Jan Change
0.1855 ^USD	-11.68%		-.--%	-19.35%

04-15	Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

May 15, 2020 at 04:36 pm

Qrons Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced operating loss was USD 218,938 compared to USD 263,514 a year ago. Net loss was USD 240,132 compared to USD 261,461 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.

Latest news about Qrons Inc.

Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-15	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Qrons Inc. Announces the Filing of A Provisional Patent Application in Furtherance of Its Neuronal and Infectious Disease Treatments Development, Including Sepsis	23-08-14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Qrons Files U.S. National Phase of Its Patent Application in Furtherance of Its Qs200 Product Candidate for Therapeutic Polypseudorotaxane Hydrogels	23-03-22	CI
Qrons Announces a New Pre-Clinical Research Program to Test the Efficacy of Tellurium Based Compounds, in Combination with its QS200(TM) Product Candidate or Independently, in Treating Diffused Axonal Injuries and Antibiotic Resistant Bacteria and Sepsis	22-12-14	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Qrons Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-11	CI
Qrons Inc. Auditor Raises 'Going Concern' Doubt	22-03-10	CI
Qrons Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
Qrons Inc. announced that it has received $0.115 million in funding from Quick Capital, LLC	21-06-14	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Qrons Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
Qrons Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Qrons Inc. announced that it has received $0.1 million in funding	20-09-22	CI
Qrons Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Qrons Inc. announced a financing transaction	20-08-10	CI
Qrons Inc. cancelled the transaction announced on May 21, 2019	20-05-20	CI
Qrons Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-15	CI

Chart Qrons Inc.

Duration

Period

More charts

Company Profile

Qrons Inc. is a biotechnology company. The Company is focuses on developing biotech products, treatments, and technologies to combat neuronal and infectious diseases with a focus on antibiotic resistant bacteria. It has developed a treatment that integrates proprietary, engineered mesenchymal stem cells (MSCs), 3D printable implant, smart materials, and a novel delivery system. The Company has developed two product candidates for treating penetrating and non-penetrating (concussion-like) traumatic brain injuries (TBIs), both integrating proprietary, anti-brain inflammation synthetic hydrogel and modified MSCs. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic hydrogel for the treatment of diffused injuries commonly referred to as concussions. The Company researches in the fields of regenerative medicine, tissue engineering and 3D printable hydrogels.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QRONS INC.	-19.35%	2.53M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research